Public educational draft · 04 November 2026Clinical review pending →

Original AXON short

DSIP: A Name Is Not a Sleep Guarantee

An original short lesson. Read the study context and the limits of each claim alongside the video.

Educational draft, not medical advice. Scientific and legal review are pending. Original conceptual visuals and on-screen captions. AXON Research Institute is an AXON project affiliated with AXON Peptide.

31 / 74 · 1:05 · Original AXON film

DSIP

The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.

Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.

Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.

Transcript

Discovery research | 1970s

Delta sleep-inducing peptide, or DSIP, has a name that sounds like a finished explanation. It began as a research finding in rabbits in the 1970s. [1]

Animal physiology is a starting point

Researchers linked the peptide with changes in slow-wave electrical activity. Translating that finding into a dependable treatment for human insomnia proved much less straightforward. [1] [2]

Small human study | Limited benefit

A double-blind study in sixteen people with chronic insomnia found limited changes and no improvement in subjective sleep quality. The authors did not see major therapeutic benefit. [2]

Name ≠ proven therapy

DSIP’s physiology and clinical usefulness remain unresolved in this evidence. FDA also describes safety-data gaps. An evocative name does not establish better sleep, a clear mechanism, or a safe treatment. [2] [3]

Sources and context

These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.

  1. Schoenenberger and Monnier (1977): Characterization of a delta-EEG-inducing peptide →Rabbit-origin experimental discovery and EEG findings.
  2. Effects of DSIP on sleep of chronic insomniac patients: a double-blind study →Sixteen participants, limited outcomes, no subjective sleep-quality improvement.
  3. FDA peptide safety information: Emideltide (DSIP) →Safety-data gaps for the proposed route.
Advertisement · AXON network

More of AXON.
One place to explore.

These promotional links lead to affiliated AXON websites. Their placement is separate from the educational content and does not validate any product, service or scientific claim.

You will leave this educational preview. Each destination has its own content, access requirements and privacy practices. No advertising tracker or referral parameter is added to these links.